286 related articles for article (PubMed ID: 25644968)
1. Tacrolimus decreases insulin sensitivity without reducing fasting insulin concentration: a 2-year follow-up study in kidney transplant recipients.
Chen QJ; Li J; Zuo SR; Zhang YP; Jia SJ; Yuan H; Liu SK; Cheng K; Ming YZ; Zuo XC; Luo AJ; Xie WZ; Cai JJ; Yang M; Wang JL
Ren Fail; 2015 May; 37(4):601-6. PubMed ID: 25644968
[TBL] [Abstract][Full Text] [Related]
2. Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor-α are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus.
Elens L; Sombogaard F; Hesselink DA; van Schaik RH; van Gelder T
Pharmacogenet Genomics; 2013 Dec; 23(12):649-57. PubMed ID: 24113216
[TBL] [Abstract][Full Text] [Related]
3. New-onset diabetes after transplantation: drug-related risk factors.
Santos L; Rodrigo E; Piñera C; Quintella E; Ruiz JC; Fernández-Fresnedo G; Palomar R; Gómez-Alamillo C; de Francisco A; Arias M
Transplant Proc; 2012 Nov; 44(9):2585-7. PubMed ID: 23146462
[TBL] [Abstract][Full Text] [Related]
4. Role of insulin resistance indices in predicting new-onset diabetes after kidney transplantation.
Nagaraja P; Ravindran V; Morris-Stiff G; Baboolal K
Transpl Int; 2013 Mar; 26(3):273-80. PubMed ID: 23230898
[TBL] [Abstract][Full Text] [Related]
5. CYP3A4 and GCK genetic polymorphisms are the risk factors of tacrolimus-induced new-onset diabetes after transplantation in renal transplant recipients.
Shi D; Xie T; Deng J; Niu P; Wu W
Eur J Clin Pharmacol; 2018 Jun; 74(6):723-729. PubMed ID: 29546446
[TBL] [Abstract][Full Text] [Related]
6. Predictors of new onset of diabetes after transplantation in stable renal recipients.
Shehab-Eldin W; Shoker A
Nephron Clin Pract; 2008; 110(1):c1-9. PubMed ID: 18654089
[TBL] [Abstract][Full Text] [Related]
7. KCNQ1 gene variants and risk of new-onset diabetes in tacrolimus-treated renal-transplanted patients.
Tavira B; Coto E; Díaz-Corte C; Ortega F; Arias M; Torres A; Díaz JM; Selgas R; López-Larrea C; Campistol JM; Ruiz-Ortega M; Alvarez V;
Clin Transplant; 2011; 25(3):E284-91. PubMed ID: 21355884
[TBL] [Abstract][Full Text] [Related]
8. Conversion from tacrolimus to cyclosporine in patients with new-onset diabetes after renal transplant: an open-label randomized prospective pilot study.
Rathi M; Rajkumar V; Rao N; Sharma A; Kumar S; Ramachandran R; Kumar V; Kohli HS; Gupta KL; Sakhuja V
Transplant Proc; 2015 May; 47(4):1158-61. PubMed ID: 26036543
[TBL] [Abstract][Full Text] [Related]
9. Clinical and genetic risk factors for new-onset diabetes mellitus after transplantation (NODAT) in major transplant centres in Malaysia.
Guad RM; Taylor-Robinson AW; Wu YS; Gan SH; Zaharan NL; Basu RC; Liew CSL; Wan Md Adnan WAH
BMC Nephrol; 2020 Sep; 21(1):388. PubMed ID: 32894076
[TBL] [Abstract][Full Text] [Related]
10. The incidence of posttransplantation diabetes mellitus during follow-up in kidney transplant recipients and relationship to Fok1 vitamin D receptor polymorphism.
Yao B; Chen X; Shen FX; Xu W; Dong TT; Chen LZ; Weng JP
Transplant Proc; 2013; 45(1):194-6. PubMed ID: 23375298
[TBL] [Abstract][Full Text] [Related]
11. New-onset diabetes after transplantation (NODAT): an evaluation of definitions in clinical trials.
First MR; Dhadda S; Croy R; Holman J; Fitzsimmons WE
Transplantation; 2013 Jul; 96(1):58-64. PubMed ID: 23619735
[TBL] [Abstract][Full Text] [Related]
12. Side effects of the calcineurin inhibitor, such as new-onset diabetes after kidney transplantation.
Borda B; Lengyel C; Várkonyi T; Kemény E; Ottlakán A; Kubik A; Keresztes C; Lázár G
Acta Physiol Hung; 2014 Sep; 101(3):388-94. PubMed ID: 25183511
[TBL] [Abstract][Full Text] [Related]
13. The combined effect of pre-transplant triglyceride levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation.
Porrini E; Delgado P; Alvarez A; Cobo M; Pérez L; González-Posada JM; Hortal L; Gallego R; García JJ; Checa M; Morales A; Salido E; Hernández D; Torres A
Nephrol Dial Transplant; 2008 Apr; 23(4):1436-41. PubMed ID: 18029372
[TBL] [Abstract][Full Text] [Related]
14. Adiponectin and risk of new-onset diabetes mellitus after kidney transplantation.
Bayés B; Lauzurica R; Granada ML; Serra A; Bonet J; Fontseré N; Salinas I; Romero R
Transplantation; 2004 Jul; 78(1):26-30. PubMed ID: 15257035
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up after conversion from tacrolimus to cyclosporin in renal transplant patients with new-onset diabetes mellitus after transplantation.
Batista F; Auyanet I; Torregrosa JV; Oppenheimer F
Transplant Proc; 2012 Nov; 44(9):2582-4. PubMed ID: 23146461
[TBL] [Abstract][Full Text] [Related]
16. Tacrolimus and angiotensin receptor blockers associated with changes in serum adiponectin level in new-onset diabetes after renal transplantation: single-center cross-sectional analysis.
Nishimura K; Kishikawa H; Kato T; Kobayashi Y; Fujii N; Takahara S; Ichikawa Y
Transpl Int; 2009 Jul; 22(7):694-701. PubMed ID: 19254242
[TBL] [Abstract][Full Text] [Related]
17. Incidence and risk factors of clinical characteristics, tacrolimus pharmacokinetics, and related genomic polymorphisms for posttransplant diabetes mellitus in the early stage of renal transplant recipients.
Numakura K; Satoh S; Tsuchiya N; Horikawa Y; Inoue T; Kakinuma H; Togashi H; Matsuura S; Tada H; Suzuki T; Habuchi T
Transplant Proc; 2005 May; 37(4):1865-7. PubMed ID: 15919487
[TBL] [Abstract][Full Text] [Related]
18. The study on the relationship between IRS-1 Gly972Arg and IRS-2 Gly1057Asp polymorphisms and type 2 diabetes in the Kurdish ethnic group in West Iran.
Haghani K; Bakhtiyari S
Genet Test Mol Biomarkers; 2012 Nov; 16(11):1270-6. PubMed ID: 22994406
[TBL] [Abstract][Full Text] [Related]
19. Is there a genetic predisposition to new-onset diabetes after kidney transplantation?
Reddy YN; Abraham G; Sundaram V; Reddy PP; Mathew M; Nagarajan P; Mehra N; Ramachandran A; Ali AA; Reddy YN
Saudi J Kidney Dis Transpl; 2015 Nov; 26(6):1113-20. PubMed ID: 26586047
[TBL] [Abstract][Full Text] [Related]
20. [Immunosuppressive therapy as a risk factor for new-onset diabetes after transplantation].
Allazova SS; Novikova MS; Kotenko ON; Shilov EM
Ter Arkh; 2020 Dec; 92(12):137-141. PubMed ID: 33720585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
